Colorectal cancer 3

Common Name(s)

Colorectal cancer 3

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Colorectal cancer 3" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Colorectal cancer 3" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Colorectal cancer 3" returned 135 free, full-text research articles on human participants. First 3 results:

Prospective double-blind randomized study on the efficacy and safety of an n-3 fatty acid enriched intravenous fat emulsion in postsurgical gastric and colorectal cancer patients.
 

Author(s): Cheng-Jen Ma, Jin-Ming Wu, Hsiang-Lin Tsai, Ching-Wen Huang, Chien-Yu Lu, Li-Chu Sun, Ying-Ling Shih, Chao-Wen Chen, Jui-Fen Chuang, Ming-Hsun Wu, Ming-Yang Wang, Ming-Tsan Lin, Jaw-Yuan Wang

Journal:

 

A lipid emulsion composed of soybean oil (long-chain triglycerides, LCT), medium-chain triglycerides (MCT) and n-3 poly-unsaturated fatty acids (PUFAs) was evaluated for immune-modulation efficacy, safety, and tolerance in patients undergoing major surgery for gastric and colorectal cancer.

Last Updated: 27 Jan 2015

Go To URL
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.
 

Author(s): Seung Tae Kim, Yong Sang Hong, Ho Yeong Lim, Jeeyun Lee, Tae Won Kim, Kyu-Pyo Kim, Sun Young Kim, Ji Yeon Baek, Jee Hyun Kim, Keun-Wook Lee, Ik-Joo Chung, Sang-Hee Cho, Kyung Hee Lee, Sang Joon Shin, Hye Jin Kang, Dong Bok Shin, Jae Won Lee, Sook Jung Jo, Young Suk Park

Journal:

 

We report updated progression-free survival (PFS) and overall survival (OS) data from a trial that compared capecitabine plus oxaliplatin (CapeOX) versus S-1 plus oxaliplatin (SOX) for the first-line treatment of metastatic colorectal cancer.

Last Updated: 17 Dec 2014

Go To URL
Interplay between 3'-UTR polymorphisms in the vascular endothelial growth factor (VEGF) gene and metabolic syndrome in determining the risk of colorectal cancer in Koreans.
 

Author(s): Young Joo Jeon, Jong Woo Kim, Hye Mi Park, Hyo Geun Jang, Jung O Kim, Jisu Oh, So Young Chong, Sung Won Kwon, Eo Jin Kim, Doyeun Oh, Nam Keun Kim

Journal:

 

Polymorphisms in angiogenesis-related genes and metabolic syndrome (MetS) risk factors play important roles in cancer development. Moreover, recent studies have reported associations between a number of 3'-UTR polymorphisms and a variety of cancers. The aim of this study was to investigate ...

Last Updated: 8 Dec 2014

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Colorectal cancer 3" returned 2 free, full-text review articles on human participants. First 3 results:

New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways.
 

Author(s): Arvind Dasari, Wells A Messersmith

Journal: Clin. Cancer Res.. 2010 Aug;16(15):3811-8.

 

Initial experience with the epidermal growth factor receptor monoclonal antibodies (EGFR MoAb) in unselected patients with metastatic colorectal cancer (mCRC) showed that most of the treated patients did not derive therapeutic benefit. This outcome has driven the search for biomarkers ...

Last Updated: 30 Jul 2010

Go To URL
Development of quality indicators for colorectal cancer surgery, using a 3-step modified Delphi approach.
 

Author(s): Anna R Gagliardi, Marko Simunovic, Bernard Langer, Hartley Stern, Adalsteinn D Brown

Journal: Can J Surg. 2005 Dec;48(6):441-52.

 

Little performance measurement has been undertaken in the area of oncology, particularly for surgery, which is a pivotal event in the continuum of cancer care. This work was conducted to develop indicators of quality for colorectal cancer surgery, using a 3-step modified Delphi approach.

Last Updated: 18 Jan 2006

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov